[{"from": "human", "value": "Could you provide a description of this molecule? [C][C@@H1][C][=C][Branch1][#Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][C][=Branch1][C][=O][N][Branch2][Ring2][Ring1][C][C][=N][N][Branch2][Ring1][O][C][=Branch2][Ring1][Branch1][=C][Ring1][Branch1][C][=C][C][=Branch1][=Branch2][=C][Branch1][Branch1][N][=C][Ring1][=Branch1][N][O][Ring2][Ring1][=Branch2][C][#N][C][C]"}, {"from": "gpt", "value": "The molecule is a cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. It has a role as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is a member of pyrazoles, a member of monofluorobenzenes, an aromatic ether, a nitrile, a member of benzamides, an azamacrocycle, an aminopyridine, a cyclic ether and an organic heterotetracyclic compound."}]